Tamoxifen citrate
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100800

CAS#: 54965-24-1 (citrate)

Description: Tamoxifen, also known as ICI 46474, is an antagonist of the estrogen receptor in breast tissue via its active metabolite, 4-hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a selective estrogen-receptor modulator. Tamoxifen is the usual endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting.


Price and Availability

Size Price Shipping out time Quantity
500mg USD 220 2 Weeks
1g USD 360 2 Weeks
5g USD 705 2 Weeks
10g USD 1250 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-06-03. Prices are subject to change without notice.

Tamoxifen citrate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 100800
Name: Tamoxifen citrate
CAS#: 54965-24-1 (citrate)
Chemical Formula: C32H37NO8
Exact Mass:
Molecular Weight: 563.65
Elemental Analysis: C, 68.19; H, 6.62; N, 2.49; O, 22.71


Related CAS #: 54965-24-1 (citrate)   10540-29-1 (free base)  

Synonym: ICI 46474, ICI-46474, ICI46474, NSC 180973, tamoxifen, tamoxifeni citras, Nolvadex, Novaldex

IUPAC/Chemical Name: (Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate

InChi Key: FQZYTYWMLGAPFJ-OQKDUQJOSA-N

InChi Code: InChI=1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

SMILES Code: CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O


Technical Data

Appearance:
White to off-white crystalline powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

 1: Shaikh IA, Brown I, Wahle KW, Heys SD. Enhancing cytotoxic therapies for breast and prostate cancers with polyunsaturated fatty acids. Nutr Cancer. 2010 Apr;62(3):284-96. Review. PubMed PMID: 20358465.

2: Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009 Dec;70(12):1688-97. Review. PubMed PMID: 20141708.

3: Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy. 2010 Feb;30(2):217. Review. PubMed PMID: 20099995.

4: Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet. 2010 Jan;127(1):1-17. Epub 2009 Oct 8. Review. PubMed PMID: 19823875.

5: Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review. PubMed PMID: 19147868.

6: Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33. Epub 2008 Dec 3. Review. PubMed PMID: 19111841.

7: Petrakova K, Růzicková J, Fait V. [Therapeutic approaches for breast carcinoma]. Klin Onkol. 2008;21(4):131-40. Review. Czech. PubMed PMID: 19102218.

8: Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol. 2008;630:206-19. Review. PubMed PMID: 18637493.

9: Saynak M, Cosar-Alas R, Yurut-Caloglu V, Caloglu M, Kocak Z, Uzal C. Chemotherapy and cerebrovascular disease. J BUON. 2008 Jan-Mar;13(1):31-6. Review. PubMed PMID: 18404783.

10: Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31(2):127-41. Review. PubMed PMID: 18217789.